Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
CM4Cure from Liège, company number BE0765658810, closed financial year 2025 with a result of € -152,297 after tax. For that financial year CM4Cure recorded a gross margin of € 627,195 and equity of € 1.8 million. Compared with financial year 2024, the result moved from € -358,924 to € -152,297. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.
€ 1.8 million
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -152,297
▲ 58 % less loss than in 2024
Profit after tax over the fiscal year.
€ 229,025
▼ 85% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -573,478.
People and assets in 2025
9.4
▲ 1.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 779,870
▲ 24% vs 2024
€ 83,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 347
▼ 64% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 48,326
▼ 34% vs 2024
€ 25,808 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 150,700
▼ 50% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 124,599
▲ 13% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 206,952 | € 319,501 | € 264,023 | € 627,195 | ▲ 138% |
| Profit after taxes | € -15,967 | € -24,941 | € -358,924 | € -152,297 | ▲ € 206,626 |
| Equity | € 878,866 | € 1,469,339 | € 1,677,124 | € 1,771,654 | ▲ 6% |
| Total debts | € 398,846 | € 909,594 | € 2,754,239 | € 2,796,078 | ▲ 2% |
| Cash | € 680,561 | € 776,593 | € 1,519,710 | € 229,025 | ▼ 85% |
| Retained profit | € -37,316 | € -62,257 | € -421,181 | € -573,478 | ▼ € 152,297 |
| Bank debt | € 100,000 | € 96,222 | € 72,878 | € 48,326 | ▼ 34% |
| Balance sheet total | € 1,277,712 | € 2,378,933 | € 4,431,363 | € 4,567,731 | ▲ 3% |
| Employees (FTE) | - | 4.3 | 7.7 | 9.4 | ▲ 1.7 |
By gross margin, CM4Cure ranks 5th of 27 companies with main activity “Speur- en ontwikkelingswerk op biotechnologisch gebied” in Liège that publish figures (fiscal year 2025).
Key figures of CM4Cure, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about CM4Cure the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to CM4Cure?
What happened at CM4Cure in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Noshaq Partners SCRL stepped down as director. NBB
- Cécile Oury stepped down as director. NBB
- Patrizio Lancellotti stepped down as director. NBB
- Venture Coaching SCRL stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 152,297. Source: NBB ↗
- Capital increase of € 450,000, published in the Gazette. Source: Staatsblad ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Liège. KBO
In short
From € 15,967 loss in 2022 to € 152,297 loss in 2025.
On average € 66,700 of value added per employee in 2025.
Management
Behind CM4Cure is Colm MCCarthy.
Directors
According to the 2025 annual accounts
Colm MCCarthy
Délégué à la gestion Journalière
Director · represented by Laurence Rosa
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +168 more
since 2021 · until 2027
Cécile Oury
Director
since 2021 · until 2027
since 2021 · until 2027
Director · represented by Daniel MARECHAL
Also active at: MICROBELCAPS, NOSHAQ SPIN-OFFS, PRESSES UNIVERSITAIRES DE LIEGE, SCIENCE PARK SERVICES, PHYTESIA, AGROPTIMIZE, Green SURF, Cytomine +11 more
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Avenue de l'Hôpital 1
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →Centre hospitalier universitaire de Liège
Bureau International d'Audiophonologie
CENTRE ANTICANCEREUX PRES L'UNIVERSITE DE LIEGE
Inokura
€ 6.4 million revenue · 2025
Belgian Bone Club
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Liège
Same main activity (Speur- en ontwikkelingswerk op biotechnologisch gebied), 32 active companies in Liège, largest first.
€ 2.9 million gross margin · 2024
€ 2.4 million gross margin · 2025
€ 1.6 million gross margin · 2025
€ 870,849 gross margin · 2025
€ 531,035 gross margin · 2025
€ 409,407 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Capital increase
Source: Deed ↗- OURY Vincent(inschrijver) 7.1%
- LANCELLOTTI Patrizio(inschrijver) 5.9%
- OURY Cécile(inschrijver) 5.9%
- NCHIMI LONGANG Alain(inschrijver) 4.7%
- BTE OTHMAN NAYAH Brima(inschrijver) 4.7%
- CELENTANO Carmine(inschrijver) 2.4%
- MELON Pierre(inschrijver) 2.4%
Incorporation
Source: Deed ↗- LANCELLOTTI Patrizio(fondateur) 21.9%
- OURY Cécile Alice Alphonse Ghislaine(fondateur) 21.9%
- GESVAL(simple souscripteur) 21%
- NOSHAQ SPIN-OFFS(simple souscripteur) 14%
- NCHIMI LONGANG Alain Thierry(fondateur) 10.5%
- MELON Pierre Guy Laurent Raoul Joseph(simple souscripteur) 7%
- CELENTANO Carmine(simple souscripteur) 3.5%
Details
- Company number
- 0765.658.810
- VAT number
- BE 0765.658.810
- Registered office
- Avenue de l'Hôpital 1, 4000 Liège
- Names & denominations
- CM4Cure
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 March 2021
- Peppol
- Active · Active since 30 Sept 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied